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INTRODUCTION
Microglandular adenosis (MGA) is a very rare disease and 
has not been reported in Korea. MGA often produces a pal-
pable mass that mimics breast cancer on breast examination. 
Histologically, small round glands lacking a myoepithelial lay-
er infiltrates normal stroma making it difficult to distinguish 
MGA from well-differentiated breast cancer. Despite its char-
acteristic infiltrative growth pattern, aggressive local spread or 
metastasis has not been reported, so it is recognized as a benign 
lesion. Until now, the treatment choice for MGA is observa-
tion, because MGA is known as a benign disease but more re-
cent data show that MGA is highly related to cancer. For that 
reason, a reassessment of the treatment plan is required for 
cases in which a core needle biopsy reveals MGA.
CASE REPORT
A 72-years-old woman presented with a palpable breast mass. 
On physical examination, about 2 cm of the mass was palpa-
ble at 11 o’clock and 2 cm from the right breast nipple. The 
mass was somewhat fixed to the surrounding tissues and the 
pectoralis major muscle. No nipple discharge, dimpling, or 
skin changes were noted. The mammographic finding was a 
grade 4 dense breast with benign calcifications in both breasts. 
A 1.2 cm ill-defined low echoic lesion (BIRADS category 5) 
was shown in the upper outer quadrant of the right breast on 
an ultrasonogram (Figure 1). We performed a core needle bi-
opsy to rule out breast cancer. The result of the core needle bi-
opsy was MGA, so we excised the mass completely. The excised 
mass was about 3×2 cm and 1.2×1 cm of the main mass was 
shown. The lesion was firm, nodular, and had irregular mar-
gins (Figure 2). Microscopic findings revealed many small 
glands infiltrating the fibrous stroma. The glands were regular, 
small, and lined by a single epithelial cell layer (Figure 3). Im-
munohistochemical staining was positive for S-100 protein 
(Figure 4), and the epithelial cells were negative for estrogen 
receptor. No evidence of recurrence during a breast examina-
tion and ultrasonogram was found at the 6-month follow-up. 
DISCUSSION
MGA of the breast is known as a benign proliferative glan-
dular lesion and was first described in 1968 by McDivitt et al. [1]. 
MGA can mimic well differentiated breast cancer both clini-
cally and pathologically [2]. All reported patients with MGA 
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Microglandular adenosis (MGA) of the breast is a very rare and 
benign proliferative lesion. Most patients complain of a palpable 
breast mass that may arouse a clinical suspicion of breast can-
cer. Histopathologically, it is hard to distinguish MGA from breast 
cancer because of the lack of a myoepithelial layer and infiltra-
tive proliferation. Several studies have reported a strong relation-
ship between MGA and carcinoma arising in MGA, so the mass 
should be excised completely in cases of MGA determined from 
a core needle biopsy rather than observation. A 72-years-old 
woman presented with a palpable breast mass. On physical ex-
amination, a mass was palpable in the right upper outer quadrant 
area and somewhat fixed to the surrounding tissues and pectora-
lis major muscle. We could not detect any mass or dense lesion 
on mammography because of a grade 4 dense breast. Ultraso-
nographic findings revealed a low echoic lesion with indistinct 
margins. The result of a core needle biopsy was MGA, which was 
confirmed by excision. We report one case of MGA, which was 
believed to breast cancer clinically.
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are women, ranging in age from 28 to 82 years. Most patients 
complain of a palpable breast mass or breast thickening that 
may arouse a clinical suspicion of carcinoma. MGA can also 
be found incidentally [2]. It is often 3 to 4 cm in size, but oc-
casionally the lesion can be greater than 20 cm, and the mar-
gin is usually ill-defined or infiltrative [2]. Mammographic 
findings of MGA may show increased density or calcifications 
stimulating breast cancer and lead to a core needle biopsy.
Histologically, MGA is characterized by a haphazard infiltra-
tion of small, uniformly open, and round glands in dense, hy-
pocellular, and fibrous tissue, or fatty mammary stroma [3,4]. 
The glands are lined by a monolayer of flat to cuboidal epithe-
lial cells that lack a myoepithelial layer (Figure 3) [2], which 
can be verified by immunohistochemistry. MGA immunohis-
tochemistry is positive for pancytokeratin and negative for 
smooth muscle actin (Figures 5, 6), so the lesion is often con-
fused with a tubular carcinoma. The absence of stromal des-
moplasia and the presence of a thickened basement membrane 
help distinguish MGA from carcinoma [5,6]. MGA has no lob-
ular grouping and frequently overruns normal elements, but 
it does not invade the perineurium or vasculature. Epithelial 
cells often lack apical snouts and have vacuolated or clear cy-
toplasm that contains glycogen [2,7]. The lumens of the glands 
contain clear or eosinophilic colloid-like secretions, usually 
positive for PAS and mucicarmine, and occasionally luminal 
calcification [5,8]. The glands are completely invested by a base-
ment membrane that can be highlighted by type IV collagen, 
laminin, or PAS staining [7,9]. MGA has no myoepithelial cells, 
and the epithelial cells are usually positive for cytokeratin and 
S-100 protein (Figures 4, 5). The epithelial cells are also posi-
tive for CAM 5.2, AE-1, and cathepsin D. but negative for es-
trogen receptor (ER), progesterone receptor (PR), and human 
Figure 3. Microscopic finding of microglandular adenosis (MGA). Infil-
trating round glands lacking a myoepithelial layer are seen with luminal 
eosinophilic secrestions. The glands are regular and small, and are lined 
by single epithelial layer (H&E stain, ×40). 
Figure 4. Immunohistochemistry (IHC) of microglandular adenosis 
(MGA). IHC of MGA shows positive for S-100 protein (IHC stain, ×40). 
Figure 1. Ultrasonographic finding of microglandular adenosis. Ill-de-
fined low echoic lesion (BIRADS category 5) in the upper outer quad-
rant of right breast was shown in ultrasonogram.
Figure 2. Gross appearance of microglandular adenosis (MGA). This is 
a gross appearance of MGA. Hematoma in the mass is result of the 
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epidermal growth factor receptor 2 (HER2/neu) [7,8,10,11]. 
The epithelial cells are also negative for epithelial membrane 
antigen and gross cystic disease fluid protein 15 as well [5], 
which is unusual in epithelial breast cancer. 
A spectrum of lesions, ranging from typical MGA to atypi-
cal MGA and carcinoma arising in MGA (MGACA), has been 
described [3,11-13]. Atypical MGA (MGA with atypia or 
AMGA) has features of classic MGA but increased irregulari-
ty, density of glands, and cytologic atypia such as hyperchro-
masia, prominent nucleoli, apoptosis compared to uncompli-
cated MGA [8]. AMGA shows a more pleomorphic admixture 
of connected microacini and larger glands and often discloses 
budding glandular units and luminal bridging. Intraluminal 
secretions are usually reduced or absent, instead cellular expan-
sion often fills the lumen. Approximately 5-10% of AMGAs 
have increased Ki67 or p53 labeling, which can be important 
differential points between MGA and AMGA [8,11,13], as well 
as important prognostic factors [13]. AMGA probably repre-
sents an intermediate lesion in the morphological transition 
from MGA to invasive carcinoma [8,11,13].
MGACA may show both carcinoma in situ, and invasive 
carcinoma and has been reported in up to 27% of cases [3,14]. 
MGA is distinct from mammary carcinoma. The carcinoma 
component arising in MGA shows various histological features 
consisting largely of solid nests and glands expanded and filled 
with cytologically malignant cells. A solid expansile prolifera-
tion obliterating the lumen, and severe cytological atypia with 
frequent apoptotic or mitotic features are observed with an in 
situ carcinoma [4]. In situ carcinoma tends to retain the un-
derlying alveolar growth pattern of MGA, but invasive foci are 
formed by the coalescent growth of expanding alveolar of in 
situ carcinoma elements, associated with a desmoplastic stro-
mal reaction and often accompanied by lymphocytic infiltra-
tion [5]. The epithelial cells may exhibit cytoplasmic clearing 
and glandular changes comparable to those of MGA. Duct 
forming carcinoma tends to retain the acinar budding pattern 
of AMGA, but it can be distinguished by its high mitotic rate, 
more pronounced cytological abnormality, necrosis, and des-
moplastic stromal reaction. The basement membrane, which 
is usually preserved around the glands of MGA and AMGA, 
tends to be disrupted in MGACA [15].
The immunohistochemical profile of MGACA is similar to 
MGA itself [5,7]. As previously stated, MGA has no myoepi-
thelial cell layer, and the epithelial cells are usually positive for 
cytokeratin 7 and S-100 protein (Figure 4) but negative for ER, 
PR, and HER2/neu. In this context, MGA, AMGA, in situ car-
cinoma, and invasive carcinoma have a similar immunohisto-
chemical profile [7,8,11,13]. A basement membrane is present 
in MGA and AMGA, whereas in situ carcinoma is defined by 
an immunohistochemical study for type IV collagen, laminin, 
or PAS stain, which is absent in invasive carcinoma [4]. Invasive 
carcinoma shows a higher percentage of staining for MIB-1 (a 
cell proliferation marker) and p53 than does AMGA.
Despite its characteristic infiltrative growth pattern, aggres-
sive local spread or metastasis has not been observed, so MGA 
is classified as a benign proliferative disease. But, although MGA 
is a benign lesion, if it is not excised completely, it may recur 
[15]. Whether MGA is a precancerous lesion or innocent by-
stander can be debated [4]. But, recent studies have found a 
strong relationship between MGA and MGACA, so the cur-
rent management for MGA is complete excision, and the ex-
cised specimen needs to be sampled thoroughly to rule out the 
possibility of an associated carcinoma. However, such a rela-
tionship is uncertain because of the rarity of the disease. A wide 
excision with a clear resection margin and careful follow-up is 
needed for AMGA. Re-excision is recommended in cases with 
Figure 5. Immunohistochemistry (IHC) of microglandular adenosis (MGA). 
IHC of MGA shows positive for pan-cytokeratin (IHC stain, ×400). 
Figure 6. Immunohistochemistry (IHC) of microglandular adenosis 
(MGA). IHC of MGA shows negative for SMA (IHC stain, ×400). Microglandular Adenosis 75
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margins positive for AMGA; however, the assessment of sur-
gical margins in carcinomas remains controversial. S-100 stain-
ing is helpful to obtain a tumor-free resection margin. The 
prognosis for MGACA varies [8,13], but most cases of carci-
noma arising in MGA have a relatively favorable prognosis 
despite being ER and PR negative. Adjuvant chemotherapy is 
recommended for patients with axillary lymph node metasta-
sis [2].
MGA, AMGA, and MGACA display similar pathological 
and immunohistochemical features, but their prognoses are 
much different. To mistake MGA for sclerosing adenosis or a 
tubular adenoma results in undertreatment, whereas misdiag-
nosing MGA as MGACA results in overtreatment. Therefore, 
distinguishing MGA from AMGA or MGACA and appropri-
ate management is very important.
In conclusion, MGA of the breast is a very rare benign dis-
ease that can mimic breast cancer clinically and pathologically. 
An MGA mass should be completely excised based on a core 
needle biopsy result because of its strong relationship with breast 
cancer.
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